Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

Beta-Secretase (BACE) Inhibitors Pipeline Analysis

P&S Market Research-Beta Secretase Inhibitors Pipeline Analysis report

Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: February 2017
Report Code: LS10801
Available Format: pdf
Pages: 89

Pipeline Overview

BACE is a cleaving enzyme of aspartyl protease with beta-secretase activity. It acts as a precursor of beta-amyloid (Aβ) protein. In Alzheimer’s disease, the Aβ protein fragments get accumulated in plaques in the brain. BACE initiates Aβ production by cleaving amyloid precursor protein (APP) to generate APPβ and C99, which is critical for the subsequent cleavage of C99 by gamma-secretase to release Aβ1-40 and Aβ1-42. Inhibition of BACE enzyme disrupts the production of toxic Aβ and forms plaque and new soluble oligomers.

Alzheimer’s disease is a common type of dementia and a fatal illness. It includes memory loss and loss of other intellectual abilities, which results in serious interference with daily life. Around 60% to 80% of dementia cases turn out to be Alzheimer’s disease. It causes problems with behavior, thinking and memory. Symptoms usually develop at a slow rate and become worse with time, causing severe interference with daily routine. The efficient inhibition of BACE is expected to stop the progression of Alzheimer’s disease. BACE inhibitors as drug candidates will block Aβ enzyme, which would prevent the buildup of beta-amyloid and may also help to reduce or halt Alzheimer’s disease.

Although significant progress has been witnessed in BACE inhibitor development, studies are still focused on BACE inhibitors with high potential, and reduced or no side effects. Also, even after promising growth in the development of BACE inhibitors, BACE therapeutics for Alzheimer’s disease treatment are still not available in the market due to the difficulty in the designing of BACE1 inhibitor drugs that can pass the blood–brain barrier.

Pipeline Analysis

As of February 2017, the BACE inhibitors pipeline comprised 15 product candidates, of which three are in Phase III stage, three in Phase II stage, one is in Phase I stage, and one in the Discovery stage. The development of two BACE inhibitor candidates were found to be inactive, and five products were discontinued.

BACE Inhibitors Pipeline Analysis

Pharma giants such as AstraZeneca plc, Eisai Co., Ltd., and Merck Sharp & Dohme Corporation, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Janssen Pharmaceuticals, Inc. and CoMentis, Inc. are actively involved in the development of BACE inhibitors. Lanabecestat is a BACE inhibitors being developed by AstraZeneca plc, in Phase III clinical stage for the treatment of Alzheimer’s disease. It is a small molecule administered by oral route.

In August 2016, AstraZeneca plc and Eli Lilly and Company received Fast Track designation by the US Food and Drug Administration (FDA) for AZD3293, a BACE inhibitor drug candidate for the treatment of Alzheimer’s disease.

Competitive Landscape

Several companies are involved in the development of BACE inhibitors pipeline, with their products in different phases. Eli Lilly and Company is developing two products, which are in Phase I and Phase II stage. Novartis Pharmaceuticals Corporation, Janssen Pharmaceuticals, Inc. and Eli Lilly and Company, each have their candidate in Phase II stage of development. Eli Lilly and Company also has its BACE inhibitor drug candidate in Phase I stage of development. CoMentis, Inc. has two drug candidates in Phase I and Discovery stage of development respectively. However, the development of one of the BACE inhibitor drug candidate of CoMentis, Inc. was found to be inactive.

Some of the key players developing BACE inhibitors pipeline are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Eisai & Co., Ltd., CoMentis, Inc., vTv Therapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Boehringer Ingelheim GmbH.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

1850
Group License

Group License authorizes access of the publication upto 5 users.

2500
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

3500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

5000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment